Trusted Resource for Clinical Trials, Protocols & Progress
Integrating In Silico Modeling and PBPK with Phase 0 Studies Integrating In Silico Modeling and PBPK with Phase 0 Studies Introduction: Enhancing Predictive Power of Early Trials Phase 0 trials offer real human PK data at microdose levels—but alone, they can’t predict full-dose behavior for every compound. To bridge this gap, researchers increasingly rely on…
Read More “Integrating In Silico Modeling and PBPK with Phase 0 Studies” »
Global Regulatory Landscape for Phase 0 Studies: A Comparative Guide Global Regulatory Landscape for Phase 0 Clinical Trials: A Comparative Overview Introduction: Regulatory Oversight in Early Human Studies Phase 0 trials—or exploratory microdosing studies—may be low-risk, but they are still subject to stringent regulatory oversight. Each country has unique pathways for approval, risk classification, and…
Read More “Global Regulatory Landscape for Phase 0 Studies: A Comparative Guide” »
How to Use Phase 0 Data to Inform Go/No-Go Decisions in Drug Development Making Go/No-Go Decisions Using Phase 0 Trial Data Why Early Decision-Making Is Critical Drug development is time-consuming and resource-intensive. Making informed go/no-go decisions as early as possible can prevent costly failures later. Phase 0 trials, through microdosing and focused pharmacokinetic/pharmacodynamic (PK/PD) evaluations,…
Read More “How to Use Phase 0 Data to Inform Go/No-Go Decisions in Drug Development” »
Phase 0 Trial Setup: Team Roles, Site Selection, and Volunteer Management Setting Up a Phase 0 Trial: Teams, Sites, and Volunteer Management Why Setup Matters in Phase 0 Trials While Phase 0 studies are shorter and involve fewer participants than traditional trials, their setup requires meticulous planning and coordination. These trials often involve advanced technologies…
Read More “Phase 0 Trial Setup: Team Roles, Site Selection, and Volunteer Management” »
Clinical Pharmacokinetics in Phase 0: How to Analyze Microdose Data How to Analyze Pharmacokinetic Data in Phase 0 Microdosing Trials Introduction: Why Pharmacokinetics (PK) Matters in Phase 0 The main objective of most Phase 0 trials is to gather pharmacokinetic (PK) data in humans using microdose levels. These early insights help answer crucial questions such…
Read More “Clinical Pharmacokinetics in Phase 0: How to Analyze Microdose Data” »
Bioanalytical Methods and Assay Development for Microdose Studies Bioanalytical Techniques and Assay Development for Phase 0 Microdosing Trials Why Bioanalysis is Crucial in Microdose Studies In Phase 0 trials, drug doses are so small that plasma concentrations are often in the picogram to nanogram range. This means standard analytical methods may not be sensitive enough…
Read More “Bioanalytical Methods and Assay Development for Microdose Studies” »
Step-by-Step Guide to Regulatory Submissions for Phase 0 Trials Step-by-Step Guide to Regulatory Submissions for Phase 0 Clinical Trials Introduction: Regulatory Oversight in Phase 0 Trials Phase 0 trials, although short and low-risk, are still governed by regulatory frameworks. Before starting human studies, sponsors must obtain authorization from national health authorities. This ensures that human…
Read More “Step-by-Step Guide to Regulatory Submissions for Phase 0 Trials” »
Ethics and Safety in Phase 0 Trials: What You Need to Know Ethics and Safety in Phase 0 Trials: What Every Researcher Should Know Introduction: Ethics at the Heart of Human Research Even though Phase 0 trials involve microdoses and no therapeutic intent, they are still clinical trials involving human participants. This means they must…
Read More “Ethics and Safety in Phase 0 Trials: What You Need to Know” »
Selecting the Right Candidates for Phase 0: Drug Selection Criteria How to Choose the Right Drug Candidates for Phase 0 Clinical Trials Why Drug Selection Matters in Phase 0 Trials Not every drug candidate is suitable for a Phase 0 microdosing study. These trials are designed to generate early pharmacokinetic (PK) and pharmacodynamic (PD) data…
Read More “Selecting the Right Candidates for Phase 0: Drug Selection Criteria” »
How to Design a Microdosing Study in Phase 0 Trials A Step-by-Step Guide to Designing a Microdosing Study for Phase 0 Trials What is a Microdosing Study? A microdosing study involves the administration of extremely low, sub-therapeutic doses of a drug to human subjects to evaluate early pharmacokinetic (PK) and pharmacodynamic (PD) behavior. These studies…
Read More “How to Design a Microdosing Study in Phase 0 Trials” »
